CABG Announces CE Mark Clinical Trial Initiation

CABG Medical has initiated enrollment in its clinical trial for CE Mark approval of the Holly Graft System, a drug-eluting graft for facilitating a coronary artery bypass procedure.

The first patient enrolled in the Holly Graft System clinical trial (second patient treated) was completed by Peter Tesar and Trevor Fayers, cardiac surgeons at the Prince Charles Hospital in Brisbane, Australia. The surgeons in Australia also completed the first implant of the Holly Graft System in November 2004.

"The incorporation of the paclitaxel drug-eluting technology into the Holly Graft System has made a profound difference that could positively impact the effectiveness of the device," said CABG CEO Manny Villafana.